Jazz Pharmaceuticals plc (JAZZ) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $248.20M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $336.60M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $57.51M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$686.40M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $248.20M | (m) | $1.21B | (m) | $18.10M* | $415.70M* | (m) | (m) | $389.20M | $18.10M |
| 2026-03-31 | Reported | (m) | $336.60M | (m) | $1.07B | (m) | $19.70M | $408.20M | (m) | (m) | $352.70M | $6.10M |
| 2025-09-30 | Reported | (m) | $57.51M | (m) | $1.13B | (m) | $15.22M* | $474.65M* | (m) | (m) | $530.65M | -$242.42M |
| 2025-06-30 | Reported | (m) | -$686.40M | (m) | $1.05B | (m) | $12.90M* | $88.80M* | (m) | (m) | $358.40M | -$17.20M |
| 2025-03-31 | Reported | (m) | -$55.90M | (m) | $897.80M | (m) | $13.90M | $429.80M | (m) | (m) | $514.00M | -$17.80M |
| 2024-09-30 | Reported | (m) | $260.21M | (m) | $1.05B | (m) | $10.79M* | $398.75M* | (m) | (m) | $325.77M | -$14.53M |
| 2024-06-30 | Reported | (m) | $199.44M | (m) | $1.02B | (m) | $7.09M* | $331.35M* | (m) | (m) | $338.52M | -$30.65M |
| 2024-03-31 | Reported | (m) | $66.21M | (m) | $901.98M | (m) | $6.90M | $267.23M | (m) | (m) | $351.71M | $11.67M |
| 2023-09-30 | Reported | (m) | $172.39M | (m) | $972.14M | (m) | $4.30M* | $307.19M* | (m) | (m) | $308.31M | -$47.18M |
| 2023-06-30 | Reported | (m) | $157.64M | (m) | $957.32M | (m) | $5.74M* | $296.76M* | (m) | (m) | $340.84M | -$24.32M |
| 2023-03-31 | Reported | (m) | $126.06M | (m) | $892.81M | (m) | $3.82M | $320.71M | (m) | (m) | $297.92M | -$15.32M |
| 2022-09-30 | Reported | (m) | $24.76M | (m) | $940.65M | (m) | -$4.90M* | $417.99M* | (m) | (m) | $358.48M | -$43.03M |
| 2022-06-30 | Reported | (m) | $85.55M | (m) | $932.88M | (m) | $12.28M* | $303.04M* | (m) | (m) | $366.47M | -$16.11M |
| 2022-03-31 | Reported | (m) | $87.55M | (m) | $813.72M | (m) | $12.29M | $208.98M | (m) | (m) | $308.81M | $536.00K |
| 2021-09-30 | Reported | (m) | $28.37M | (m) | $838.12M | (m) | $8.33M* | $274.06M* | (m) | (m) | $363.68M | -$18.06M |
| 2021-06-30 | Reported | (m) | -$69.59M | (m) | $751.81M | (m) | $7.18M* | $41.70M* | (m) | (m) | $429.03M | $228.62M |
| 2021-03-31 | Reported | (m) | $162.12M | (m) | $607.58M | (m) | $2.17M | $285.00M | (m) | (m) | $260.51M | $18.02M |
| 2020-09-30 | Reported | (m) | $196.21M | (m) | $600.89M | (m) | $3.37M* | $257.89M* | (m) | (m) | $207.25M | $19.28M |
| 2020-06-30 | Reported | (m) | $198.13M | (m) | $562.44M | (m) | $2.69M* | $182.52M* | (m) | (m) | $191.41M | $54.75M |
| 2020-03-31 | Reported | (m) | -$189.67M | (m) | $534.73M | (m) | $4.83M | $272.97M | (m) | (m) | $208.40M | -$51.29M |
| 2019-09-30 | Reported | (m) | $133.10M | (m) | $537.70M | (m) | $11.09M* | $337.50M* | (m) | $79.86M | $178.71M | $10.90M |
| 2019-06-30 | Reported | (m) | $204.28M | (m) | $534.13M | (m) | $13.96M* | $148.85M* | (m) | $62.38M | $176.01M | -$78.65M |
| 2019-03-31 | Reported | (m) | $133.74M | (m) | $508.19M | (m) | $7.95M | $202.25M | (m) | $60.10M | $167.95M | $29.12M |
| 2018-09-30 | Reported | (m) | $188.78M | (m) | $469.37M | (m) | (m) | $221.47M* | (m) | $51.16M | $155.87M | $19.35M |
| 2018-06-30 | Reported | (m) | $153.20M | (m) | $500.48M | (m) | (m) | $191.97M* | (m) | $56.13M | $158.58M | $36.52M |
| 2018-03-31 | Reported | (m) | $87.81M | (m) | $444.61M | (m) | (m) | $167.36M | (m) | $62.67M | $207.21M | $19.15M |
| 2017-09-30 | Reported | (m) | $86.45M | (m) | $411.86M | (m) | (m) | $188.90M* | (m) | $47.36M | $124.52M | $1.24M |
| 2017-06-30 | Reported | (m) | $165.04M | (m) | $394.39M | (m) | (m) | $135.09M* | (m) | $40.16M | $132.33M | $35.52M |
| 2017-03-31 | Reported | (m) | $136.14M | (m) | $376.05M | (m) | (m) | $164.54M | (m) | $44.93M | $144.25M | $29.16M |
| 2016-09-30 | Reported | (m) | $136.25M | (m) | (m) | (m) | (m) | $133.03M* | (m) | $47.80M | $124.37M | $26.44M |
| 2016-06-30 | Reported | (m) | $168.74M | (m) | (m) | (m) | (m) | $127.01M* | (m) | $39.09M | $122.62M | $42.11M |
| 2016-03-31 | Reported | (m) | $121.16M | (m) | (m) | (m) | (m) | $151.65M | (m) | $31.25M | $128.76M | $32.34M |
| 2015-09-30 | Reported | (m) | $131.53M | (m) | (m) | (m) | (m) | $175.08M* | (m) | $50.78M | $104.04M | $29.95M |
| 2015-06-30 | Reported | (m) | $153.30M | (m) | (m) | (m) | (m) | $140.57M* | (m) | $27.83M | $107.13M | $30.65M |
| 2015-03-31 | Reported | (m) | $116.76M | (m) | (m) | (m) | (m) | $96.56M | (m) | $27.18M | $112.39M | $32.06M |
| 2014-09-30 | Reported | (m) | $58.04M | (m) | (m) | (m) | (m) | $129.70M* | (m) | $22.42M | $93.50M | $24.22M |
| 2014-06-30 | Reported | (m) | $74.29M | (m) | (m) | (m) | (m) | $74.92M* | (m) | $20.09M | $100.56M | $19.35M |
| 2014-03-31 | Reported | (m) | -$66.66M | (m) | (m) | (m) | (m) | $68.72M | (m) | $18.11M | $106.36M | $17.03M |
| 2013-09-30 | Reported | (m) | $100.56M | (m) | (m) | (m) | (m) | $130.79M* | (m) | $11.83M | $74.97M | $18.34M |
| 2013-06-30 | Reported | (m) | $77.07M | (m) | (m) | (m) | (m) | $8.72M* | (m) | $9.25M | $77.51M | $23.61M |
| 2013-03-31 | Reported | (m) | $68.19M | (m) | (m) | (m) | (m) | $69.89M | (m) | $6.75M | $70.53M | $17.63M |
| 2012-09-30 | Reported | (m) | $55.30M | (m) | (m) | (m) | (m) | $44.14M* | (m) | $6.92M | $60.92M | $12.86M |
| 2012-06-30 | Reported | (m) | $39.43M | (m) | (m) | (m) | (m) | $76.97M* | (m) | $2.32M | $57.22M | $6.59M |
| 2012-03-31 | Reported | (m) | $35.74M | (m) | (m) | (m) | (m) | $24.30M | (m) | $3.96M | $44.36M | $5.52M |
| 2011-09-30 | Reported | (m) | $33.70M | (m) | (m) | (m) | (m) | $46.05M* | (m) | $3.28M | $30.55M | $0.00 |
| 2011-06-30 | Reported | (m) | $33.86M | (m) | (m) | (m) | (m) | $37.44M* | (m) | $3.38M | $22.09M | $0.00 |
| 2011-03-31 | Reported | (m) | $22.60M | (m) | (m) | (m) | (m) | $24.45M | (m) | $3.69M | $19.91M | (m) |
| 2010-09-30 | Reported | (m) | $14.44M | (m) | (m) | (m) | (m) | $18.49M* | (m) | $7.32M | $18.04M | (m) |
| 2010-06-30 | Reported | (m) | $10.58M | (m) | (m) | (m) | (m) | (m) | (m) | $7.96M | $17.10M | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | (m) | (m) | (m) | -9.11% | $58.75M | $1.36B | (m) | (m) | $1.81B | -$272.44M |
| 2024-12-31 | Reported | (m) | (m) | (m) | (m) | 18.42% | $38.07M | $1.40B | (m) | (m) | $1.39B | -$91.43M |
| 2023-12-31 | Reported | (m) | (m) | (m) | (m) | 15.88% | $23.96M | $1.09B | (m) | (m) | $1.34B | -$119.91M |
| 2022-12-31 | Reported | (m) | (m) | (m) | (m) | -0.96% | $29.05M | $1.27B | (m) | (m) | $1.42B | -$158.65M |
| 2021-12-31 | Reported | (m) | (m) | (m) | (m) | 6.37% | $27.64M | $778.51M | (m) | (m) | $1.45B | $216.12M |
| 2020-12-31 | Reported | (m) | (m) | (m) | (m) | 16.79% | $15.00M | $899.65M | (m) | (m) | $854.23M | $33.52M |
| 2019-12-31 | Reported | (m) | (m) | (m) | (m) | 25.33% | $40.13M | $776.40M | (m) | $299.73M | $736.94M | -$73.15M |
| 2018-12-31 | Reported | (m) | (m) | (m) | (m) | 33.32% | $20.37M | $798.90M | (m) | $226.62M | $683.53M | $80.16M |
| 2017-12-31 | Reported | (m) | (m) | (m) | (m) | 33.48% | (m) | $693.09M | (m) | $198.44M | $544.16M | -$47.74M |
| 2016-12-31 | Reported | (m) | (m) | (m) | (m) | 40.56% | (m) | $592.39M | (m) | $162.30M | $502.89M | $135.24M |
| 2015-12-31 | Reported | (m) | (m) | (m) | (m) | 39.11% | (m) | $531.94M | (m) | $135.25M | $449.12M | $106.40M |
| 2014-12-31 | Reported | (m) | $195.59M | (m) | (m) | (m) | (m) | $407.61M | (m) | $85.18M | $406.11M | $94.23M |
| 2013-12-31 | Reported | (m) | $340.31M | (m) | (m) | (m) | (m) | $288.43M | (m) | $41.63M | $304.30M | $91.64M |
| 2012-12-31 | Reported | (m) | $197.84M | (m) | (m) | (m) | (m) | $249.75M | (m) | $20.48M | $223.88M | -$83.79M |
| 2011-12-31 | Reported | (m) | $127.83M | (m) | (m) | (m) | (m) | $151.60M | (m) | $14.12M | $108.94M | $0.00 |
| 2010-12-31 | Reported | (m) | $57.79M | (m) | (m) | (m) | (m) | $58.87M | (m) | $25.61M | $69.00M | $0.00 |
| 2009-12-31 | Reported | (m) | $15.93M | (m) | (m) | (m) | (m) | -$15.88M | (m) | $36.56M | $58.65M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |